Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 20/20 | 0.52 |
| ▸ | PLG | P00747 | 1/20 | 0.49 |
| ▸ | PROC | P04070 | 1/20 | 0.49 |
| ▸ | F2 | P00734 | 8/20 | 0.48 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.47 |
| ▸ | HPN | P05981 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7418864 | 1.00 | F10 (0.52) | F10PLGPROCF2PRSS1 | |
| Trifluoroacetic Acid SCHEMBL8834435 | 1.00 | F10 (0.52) | F10PLGPROCF2PRSS1 | |
| Trifluoroacetic Acid SCHEMBL7421270 | 1.00 | F10 (0.52) | F10PLGPROCF2PRSS1 | |
| Trifluoroacetic Acid SCHEMBL7423936 | 0.94 | F10 (0.51) | F10PLGPROCF2PRSS1 | |
| Trifluoroacetic Acid SCHEMBL7421812 | 0.93 | F10 (0.51) | F10PLGPROCF2PRSS1 | |
| SCHEMBL7413859 | 0.92 | F10 (0.56) | F10PLGPROCF2 | |
| Trifluoroacetic Acid SCHEMBL7422044 | 0.89 | F10 (0.48) | F10PLGPROCF2PRSS1 | |
| Trifluoroacetic Acid SCHEMBL7476153 | 0.88 | F10 (0.53) | F10PLGPROCF2PRSS1 | |
| Trifluoroacetic Acid SCHEMBL7424775 | 0.87 | F2 (0.42) | F10F2PRSS1HPNPRSS2 | |
| Trifluoroacetic Acid SCHEMBL7423077 | 0.86 | PRMT6 (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1810693-A2 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | Shering Corporation (US) | 2007-07-25 | — | — | EP | claimed |
| EP-1353694-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | Schering Corporation (US) | 2003-10-22 | — | — | EP | claimed |
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | SCHERING CORPORATION | 2002-10-10 | — | — | US | claimed |
| WO-2002058734-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| EP-0853618-A4 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N- (AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHONE POULENC RORER PHARMA (US) | 2000-03-15 | — | — | EP | claimed |
| EP-0853618-A1 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N- (AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-07-22 | — | — | EP | claimed |
| US-5612353-A | ANTICOAGULANT | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-03-18 | — | — | US | claimed |
| WO-1996040679-A1 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-12-19 | — | — | WO | claimed |
| US-8623873-B2 | Substituted piperazines as CB1 antagonists | INTERVET INC. (US) | 2014-01-07 | — | — | US | disclosed |
| EP-1810971-B1 | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia | MERCK SHARP & DOHME (US) | 2013-12-25 | — | — | EP | disclosed |
| EP-1606287-B1 | SUBSTITUTED AZETIDINONE COMPOUNDS, FORMULATIONS AND USES THEREOF FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA | MERCK SHARP & DOHME (US) | 2013-10-02 | — | — | EP | disclosed |
| EP-1819684-B1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | INTERVET INT BV (NL) | 2013-08-07 | — | — | EP | disclosed |
| US-20130072468-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | GILBERT ERIC J (US) | 2013-03-21 | — | — | US | disclosed |
| EP-2548874-A2 | Substituted piperazines as CB1 antagonists | Intervet International B.V. (NL) | 2013-01-23 | — | — | EP | disclosed |
| WO-2002058732-A2 | COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) ACTIVATOR(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
| EP-0853618-A4 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N- (AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHONE POULENC RORER PHARMA (US) | 2000-03-15 | — | — | EP | disclosed |
| US-6034093-A | Substituted sulfonic acid N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 2000-03-07 | — | — | US | disclosed |
| EP-0853618-A1 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N- (AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHONE-POULENC RORER PHARMACEUTICALS, INC. (US) | 1998-07-22 | — | — | EP | disclosed |
| US-5612353-A | ANTICOAGULANT | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1997-03-18 | — | — | US | disclosed |
| WO-1996040679-A1 | SUBSTITUTED (SULFINIC ACID, SULFONIC ACID, SULFONYLAMINO OR SULFINYLAMINO) N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLYLAMIDE COMPOUNDS | RHÔNE-POULENC RORER PHARMACEUTICALS INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072468-A1 | SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS | CNR1, CNR2, GPR119 | F10 3779/4885PLG 1550/4885PROC 2233/4885 |
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | APOB, FABP2, CYP46A1 | F10 613/4885PLG 183/4885PROC 221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.